Dr. John D. Powderly II, MD
Claim this profileCarolina BioOncology Institute - Cancer Research Centre
Studies Solid Tumors
Studies Tumors
2 reported clinical trials
4 drugs studied
Affiliated Hospitals
Clinical Trials John D. Powderly II, MD is currently running
GRC 54276 + Immunotherapy
for Advanced Cancers
This is first in human (FIH) study to a) evaluate the safety and tolerability profile of GRC54276, b) determine the maximum tolerated dose (MTD) and recommended Phase 2 doses (RP2D), and c) pharmacokinetic profile of GRC54276 alone and in combination with pembrolizumab or atezolizumab in participants with advanced solid tumors and lymphomas.
Recruiting1 award Phase 1
CLN-418
for Solid Tumors
Study to evaluate the safety and tolerability of the study drug CLN-418, to determine the maximum tolerated dose and/or recommended Phase 2 study dose of CLN-418.
Recruiting1 award Phase 1
More about John D. Powderly II, MD
Clinical Trial Related2 years of experience running clinical trials · Led 2 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments John D. Powderly II, MD has experience with
- HBM7008
- Atezolizumab
- GRC 54276
- Pembrolizumab
Breakdown of trials John D. Powderly II, MD has run
Tumors
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does John D. Powderly II, MD specialize in?
John D. Powderly II, MD focuses on Solid Tumors and Tumors. In particular, much of their work with Solid Tumors has involved Stage IV patients, or patients who are undergoing treatment.
Is John D. Powderly II, MD currently recruiting for clinical trials?
Yes, John D. Powderly II, MD is currently recruiting for 2 clinical trials in Huntersville North Carolina. If you're interested in participating, you should apply.
Are there any treatments that John D. Powderly II, MD has studied deeply?
Yes, John D. Powderly II, MD has studied treatments such as HBM7008, Atezolizumab, GRC 54276.
What is the best way to schedule an appointment with John D. Powderly II, MD?
Apply for one of the trials that John D. Powderly II, MD is conducting.
What is the office address of John D. Powderly II, MD?
The office of John D. Powderly II, MD is located at: Carolina BioOncology Institute - Cancer Research Centre, Huntersville, North Carolina 28078 United States. This is the address for their practice at the Carolina BioOncology Institute - Cancer Research Centre.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.